|
Evaluating the clinical utility of circulating tumor cells (CTC) profiling to predict selection of preferred therapeutic regimens in newly diagnosed or pretreated refractory renal cell carcinomas (RCC). |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Merck Serono; Pfizer; Sanofi/Aventis |
Speakers' Bureau - Bayer; Exelixis; Pfizer |
Research Funding - Bristol-Myers Squibb; Merck KGaA |
|
|
Consulting or Advisory Role - Datar Cancer Genetics |
|
|
Consulting or Advisory Role - AstraZeneca; BMS; Merck; Pfizer |
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - BMS; Merck |
|
|
No Relationships to Disclose |
|
|
Employment - Datar Cancer Genetics |
|
|
Employment - Datar Cancer Genetics |
|
|
Employment - Datar Cancer Genetics |
|
|
No Relationships to Disclose |